The VISIONARY trial is testing sibeprenlimab, a humanized IgG2 monoclonal antibody, in patients with IgA nephropathy, a population at high risk for kidney failure.

Telitacicept is a dual inhibitor of both B-lymphocyte stimulator and a proliferation-inducing ligand, cytokines that promote B cell survival and production of pathogenic galactose-deficient IgA1.

H OUSTON -- A novel self-administered shot that inhibits two key immunoregulatory cytokines reduced proteinuria in patients ...

The benefits are observed across patient subtypes and potentially offer the chance to avoid dialysis and implement a new standard of care.